Stocktoria
Spyre Therapeutics, Inc. SYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-04-07
Chart by TradingView
2/9
Piotroski F — financial health
11.54
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$7.6B
P / B10.7×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Shareholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
| Ratios | |||||
| Operating margin | — | — | -27348.0% | -3640.2% | -350.3% |
| Net margin | — | — | -38238.1% | -3598.8% | -351.1% |
| FCF margin | — | — | -11276.5% | -3442.8% | -289.7% |
| Return on assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% |
| Return on equity | -21.7% | -40.2% | -184.1% | -166.6% | -78.4% |
| Current ratio | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 |
| Revenue growth | — | -100.0% | -62.0% | -87.6% | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 11.54 (safe)
- Working capital / assets 0.925
- Retained earnings / assets -1.45
- EBIT / assets -0.269
- Equity / liabilities 11.436
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001636282 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.